Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience

Clin Case Rep. 2021 Feb 20;9(4):2162-2167. doi: 10.1002/ccr3.3970. eCollection 2021 Apr.

Authors

Ouissam Al Jarroudi^{1

2

3}, Hamed Chaabouni¹, Ayhan Ulusakarya¹, Wathek Almohamad¹, Yusuf Gumus¹, Emma Goldschmidt¹, Said Afqir^{2

3}, Jean-Francois Morère¹

Affiliations

¹ Medical Oncology Department AP-HP Paul Brousse Hospital Villejuif France.
² Medical Oncology Department University Hospital Mohammed VI-Oujda Oujda Morocco.
³ Faculty of Medicine and Pharmacy Mohammed Ist University Oujda Morocco.

Abstract

Nivolumab is an effective and safe treatment in HCC.

Keywords: clinical outcomes; hepatocellular carcinoma; nivolumab; survival.

© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Publication types

Case Reports